3.61

0.55% -0.02

After Hours: 3.66 0.05 +1.39%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $3.61, with a volume of 413.03K. It is down -0.55% in the last 24 hours and up +27.11% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Previous Close:

$3.63

Open:

$3.69

24h Volume:

413.03K

Relative Volume:

0.21

Market Cap:

$257.27M

Revenue:

Net Income/Loss:

$-292.19M

P/E Ratio:

-0.7521

EPS:

-4.8

Net Cash Flow:

$-208.41M

1W Performance:

+11.76%

1M Performance:

+27.11%

6M Performance:

-68.93%

1Y Performance:

-65.98%

1-Day Range:

$3.61

$3.73

1-Week Range:

$3.28

$3.73

52-Week Range:

$2.66

$18.07

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

168

Twitter

@ZentalisP

Next Earnings Date

2024-11-04

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	3.61	257.27M	0	-292.19M	-208.41M	-4.54
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

Nov 29, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World

Nov 29, 2024

Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat

Nov 29, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat

Nov 29, 2024

Nov 23, 2024

Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat

Nov 23, 2024

Nov 19, 2024

Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat

Nov 16, 2024

Nov 15, 2024

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright - MarketBeat

Nov 15, 2024

Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat

Nov 15, 2024

Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks

Nov 13, 2024

Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch

Nov 13, 2024

Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire

Nov 13, 2024

Zentalis Pharma Reshapes Leadership, Advances Cancer Drug Azenosertib Toward Key Trials | ZNTL Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Nov 12, 2024

GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat

Nov 12, 2024

Nov 08, 2024